Dr. Chun Wu is the Managing Partner of BCG Greater China, leading the firms’s business across all industry and functional practices in this region. She has been recognized as one of Fortune China’s Most Powerful Women in Business for two consecutive years (2023-2024) and was named to Forbes China’s Top Businesswomen list in 2026, reflecting her exceptional leadership and influence in the business world.

Under her strategic guidance, BCG established the Greater China Leadership Institute in 2022, providing strategic innovation and leadership development programs tailored to companies in China. It has gained recognition and popularity from C-suite executives. Meanwhile, BCG has organized hundreds of high-level exchanges among global companies and industry associations, fostering deeper collaboration between Chinese and international businesses.

With over two decades of deep expertise in the healthcare industry, Dr. Wu previously headed BCG’s Healthcare practice in Greater China before assuming leadership of the firm’s regional operations. Her extensive consulting experience spans both domestic enterprises and multinational corporations, addressing critical areas and topics including healthcare industry policy, strategic business development, new product R&D and technology platform upgrades, operational excellence, digital transformation, and organizational change. Additionally, she offers distinctive perspectives on macroeconomic and demographic shifts --including globalization and the rise of the silver economy -- alongside strategic innovation and organizational leadership, with a strong focus on addressing systemic challenges such as sustainability, long-term value creation, and AI-enabled transformation.

Dr. Wu is a frequent speaker at premier business forums, including the China Development Forum, Boao Forum for Asia, World Economic Forum Annual Meeting of the New Champions, Yangtze River Delta Integration Development Forum, International BioPharma Industry Week Shanghai, and China Pharmaceutical Entrepreneurs Scientists Investors Conference. She has coauthored numerous influential publications, such as China’s Path to a Sustainable Future released during the China Development Forum, The Guide for Sustainable Development of Chinese Corporates (2022) in collaboration with the APEC China Business Council, Why Two Hearts Are Better Than One: How to Beat Your Rivals in a Bifurcated World, China Economic Review and Outlook, Beyond Efficiency: China’s Next Leap in Biopharma Innovation, China Synthetic Biology Industry Report 2024, Chinese Pharmaceutical Companies Going Global, China Consumer Healthcare Market Outlook, China’s Medical Device Innovation series, China Pharmaceutical Innovation series, and China Vaccine Industry Transformation series.

Dr. Wu holds a B.S. degree in biochemistry from Peking University and a Ph.D. degree in Genetics from Yale University.